Dole W - Search Results

1

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W. Wigley FM, et al. Among authors: dole w. Ann Intern Med. 1994 Feb 1;120(3):199-206. doi: 10.7326/0003-4819-120-3-199402010-00004. Ann Intern Med. 1994. PMID: 7506013 Clinical Trial.

2

Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Wigley FM, et al. Among authors: dole wp. J Rheumatol. 1992 Sep;19(9):1407-14. J Rheumatol. 1992. PMID: 1279170 Clinical Trial.

3

Failure of vasoldilator infusion to alter pulmonary diffusing capacity in systemic sclerosis.

Thurm CA, Wigley FM, Dole WP, Wise RA. Thurm CA, et al. Among authors: dole wp. Am J Med. 1991 May;90(5):547-52. Am J Med. 1991. PMID: 1709338 Clinical Trial.

4

Iloprost in cardiopulmonary bypass procedures.

Watson HR, Belcher G, Brierley JK, Dole WP. Watson HR, et al. Among authors: dole wp. Agents Actions Suppl. 1992;37:346-53. doi: 10.1007/978-3-0348-7262-1_47. Agents Actions Suppl. 1992. PMID: 1378689 Clinical Trial.

5

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.

Hu P, Yin Q, Deckert F, Jiang J, Liu D, Kjems L, Dole WP, He YL. Hu P, et al. J Clin Pharmacol. 2009 Jan;49(1):39-49. doi: 10.1177/0091270008325152. Epub 2008 Oct 1. J Clin Pharmacol. 2009. PMID: 18832295 Clinical Trial.

6

Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.

Hu P, Bartlett M, Karan RS, Jiang J, Zhang S, Zhang J, Howard D, Yeh CM, Al-Fayoumi S, Jarugula V, Dole WP. Hu P, et al. Clin Drug Investig. 2010;30(4):221-8. doi: 10.2165/11533050-000000000-00000. Clin Drug Investig. 2010. PMID: 20192280 Clinical Trial.

7

Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.

Engeli S, May M, Nussberger J, Danser AHJ, Dole WP, Prescott MF, Dahlke M, Stitah S, Pal P, Boschmann M, Jordan J. Engeli S, et al. Among authors: dole wp. J Am Soc Hypertens. 2017 Aug;11(8):488-497. doi: 10.1016/j.jash.2017.06.002. Epub 2017 Jun 12. J Am Soc Hypertens. 2017. PMID: 28666704 Clinical Trial.

8

Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosenberg M, Howard D, Dole WP. Sunkara G, et al. J Clin Pharmacol. 2007 Sep;47(9):1152-8. doi: 10.1177/0091270007304313. Epub 2007 Jul 26. J Clin Pharmacol. 2007. PMID: 17656620 Clinical Trial.

9

Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.

He YL, Sabo R, Sunkara G, Bizot MN, Riviere GJ, Leon S, Ligueros-Saylan M, Dole WP, Howard D. He YL, et al. J Clin Pharmacol. 2007 Aug;47(8):998-1004. doi: 10.1177/0091270007301802. J Clin Pharmacol. 2007. PMID: 17660482 Clinical Trial.

10

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

He YL, Sabo R, Campestrini J, Wang Y, Riviere GJ, Nielsen JC, Rosenberg M, Ligueros-Saylan M, Howard D, Dole WP. He YL, et al. Br J Clin Pharmacol. 2008 Mar;65(3):338-46. doi: 10.1111/j.1365-2125.2007.03031.x. Epub 2007 Oct 24. Br J Clin Pharmacol. 2008. PMID: 17961192 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82 results

Search Page